PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.
Gabbay joins the board of the Swiss company after spending time in leadership roles with the American Diabetes Association (ADA). Peterson spent more than two decades as a medtech CEO and more recently served as executive in residence at a private equity firm.
They both bring expertise to PharmaSens, which develops a unique insulin delivery platform. The company aims to bring an all-in-one wearable patch device integrating both insulin delivery and continuous glucose monitoring to patients. PharmaSens submitted its Niia Essential insulin patch pump system for FDA approval at the end of last year.
“Welcoming Dr. Bob Gabbay and James Peterson to our board is a great honor and represents a significant milestone for PharmaSens as the company delves more deeply into the clinical research phase and looks to develop internationally,” said Jean Patricot, chair of the PharmaSens board. “Their expertise will strengthen our efforts to simplify diabetes management and expand access to insulin pump therapy for more people with diabetes.”
More about the new additions to the PharmaSens board
Gabbay spent 40 years in patient care, research and leadership within the diabetes community. He recently stepped down as chief scientific and medical officer of the ADA.
For more than 10 years, he has served as associate professor of medicine at Harvard Medical School and has cared for patients as an endocrinologist at the renowned Joslin Diabetes Center, where for his first seven years, he served as the organization’s chief medical officer. Prior to Harvard and Joslin, Dr. Gabbay held the position of professor of medicine in the college of medicine at Penn State.
Peterson brings with him extensive leadership experience in growth, M&A, corporate fundraising, venture building and new business development. He spent 23 years at global medtech company Haemonetics, where he eventually retired as president and CEO. Following his retirement, he invested in diabetes technology with private equity firm Warburg Pincus.
Additionally, Peterson has diabetes experience, founding two separate insulin delivery companies — Asante and CeQur. He also served on the Finance Committee of the ADA and on the board of the Joslin Diabetes Center. He remains a member of the clinical assessment committee with the latter.
“As we move into the next stage of our company’s development, we look forward to working with Bob and James on our board and to the guidance they will provide based on their depth and breadth of clinical and entrepreneurial experience,” said PharmaSens CEO Marcel Both.
